Momelotinib in VEXAS Syndrome

Launched by GROUPE FRANCOPHONE DES MYELODYSPLASIES · Jul 25, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medicine called momelotinib to see if it can help people with VEXAS syndrome, a rare condition that causes inflammation and blood problems. Some participants may also have a related blood disorder called myelodysplastic syndrome (MDS). The study will first find the safest dose of momelotinib and then treat patients with that dose to see if it helps control symptoms and improve their health over time.

Adults with VEXAS syndrome who have symptoms that need treatment with steroids (like prednisone) and who have not responded well or are dependent on steroids may be eligible. To join, patients need to be in fairly good overall health and able to give consent. During the study, all participants will continue taking steroids and receive momelotinib daily until their disease worsens or they stop responding. Doctors will check how well the treatment is working at several points during the first year. It’s important to know that this study is not yet open for enrollment, and certain health conditions or prior treatments may prevent someone from joining.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ECOG (Eastern Cooperative Oncology Group) performance status 0-2 at the time of screening
• • Age ≥ 18 years
• • Written informed consent
• • Diagnosis of VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory and Somatic) syndrome with UBA1 (Ubiquitin Like Modifier Activating Enzyme 1) mutation and clinically symptomatic disease requiring immunosuppressive treatment and at least 10mg/d of glucocorticoids
• • Patients with uncontrolled symptoms related to VEXAS with prior treatment line(s) (including steroids)
• • Patients refractory/dependent to steroids
• • Single concomitant steroids therapy (e.g., prednisone or equivalent) at the time of inclusion is allowed
• • For patients treated with other immunosuppressive/immunomodulatory therapy than glucocorticoids, a wash out period of 28 days is required prior momelotinib onset
• • Erythropoietin/luspatercept used as a growth factor treatment is not allowed 28 days prior enrollment
• • Adequate liver function (serum transaminases ≤ 3 x ULN (Upper Limits of Normal), Bilirubin ≤ 1.5 x ULN (isolated bilirubin \> 1.5 x ULN is acceptable if bilirubin fractionated and direct bilirubin \< 35%)
• • Adequate renal function (creatinine clearance with MDRD (Modification of Diet in Renal Disease) formula \> 30 ml/min)
• * Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must:
• • 1. Have a negative serum or urine pregnancy test within 24 hours prior to beginning treatment on this study. Lactating patients are excluded.
• • 2. Agree to use, and to be able to comply with, effective contraception without interruption, 4 weeks before starting study drug throughout the entire duration study drug therapy (including doses interruptions) and for 12 weeks after the end of the study drug therapy.
• • 3. Agree to learn about the procedures for preservation of egg before starting treatment.
• * Male patients must:
• • 1. Agree the need for the use of a condom if engaged in sexual activity with a woman of childbearing potential during the entire period of treatment, even if disruption of treatment and during 12 weeks after end of treatment.
• • 2. Agree to learn about the procedures for preservation of sperm before starting treatment.
• Exclusion Criteria:
• • Patients with MDS (Myelodysplastic syndrome) scheduled for allogeneic stem cell transplant or high risk MDS according to IWG (International Working Group) 2023
• • Patients who are or have been already treated with Janus Kinase (JAK) inhibitors for VEXAS syndrome or another indication
• • Patients who are unable to receive a starting daily dose of momelotinib of at least 100 mg
• • Subjects with any other active malignancies are not eligible, except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which subject has been disease-free for at least 3 years
• • Uncontrolled congestive heart failure (New York Heart Association Classification 3 or 4), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, transient ischemic attack, or pulmonary embolism within 12 weeks prior to initiation of momelotinib
• • Known infection with acute and chronic active Human Immunodeficiency Virus, Hepatitis B Virus, Hepatitis C Virus
• • Any medical or psychiatric condition not allowing the informed consent of the subject
• • Presence of clinically meaningful active bacterial, fungal, parasitic or viral infection which requires therapy
• • Previous history of Progressive Multifocal Leuko-encephalopathy
• • Active gastrointestinal conditions that may affect absorption
• • No affiliation to a health insurance system
• • Known hypersensitivity to the study investigational medicinal product, the metabolites, or formulation excipients